Citius Oncology, Inc. Increase (Decrease) in Due to Related Parties
Citius Oncology, Inc. (CTOR) reported Increase (Decrease) in Due to Related Parties of $471.79 thousand for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDueToRelatedParties · last filed 2026-08-14
- Citius Oncology, Inc. increase (decrease) in due to related parties for the quarter ending 2026-06-30 was $1.76M, a 30.07% decline year-over-year.
- Citius Oncology, Inc. increase (decrease) in due to related parties for the quarter ending 2026-03-31 was -$3.27M, a 260.03% decline year-over-year.
- Citius Oncology, Inc. increase (decrease) in due to related parties for the quarter ending 2025-12-31 was $1.98M, a 14.16% decline year-over-year.
- Citius Oncology, Inc. increase (decrease) in due to related parties for the quarter ending 2025-09-30 was $2.05M, a 27.40% decline year-over-year.
- Citius Oncology, Inc. increase (decrease) in due to related parties for fiscal 2025 was $8.92M, a 37.46% decline from fiscal 2024.
- Citius Oncology, Inc. increase (decrease) in due to related parties for fiscal 2024 was $14.27M.
| Period end | Increase (Decrease) in Due to Related Parties 3 month | Increase (Decrease) in Due to Related Parties 6 month | Increase (Decrease) in Due to Related Parties 9 month | Increase (Decrease) in Due to Related Parties 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | -$1.51M derived: sum of 2 quarters · filed 2026-08-14 | $471.79K 10-Q · filed 2026-08-14 | $2.52M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$3.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | -$1.29M 10-Q · filed 2026-05-15 | $757.12K derived: sum of 3 quarters · filed 2026-05-15 | $3.28M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.98M 10-Q · filed 2026-02-13 | $4.03M derived: sum of 2 quarters · filed 2026-02-13 | $6.55M derived: sum of 3 quarters · filed 2026-08-14 | $8.60M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | $2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $4.57M derived: sum of 2 quarters · filed 2026-08-14 | $6.62M derived: sum of 3 quarters · filed 2026-08-14 | $8.92M 10-K · filed 2025-12-23 |
| 2025-06-30 | $2.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-14 | $4.57M derived: sum of 2 quarters · filed 2026-08-14 | $6.88M 10-Q · filed 2026-08-14 | $9.70M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-15 | $4.35M 10-Q · filed 2026-05-15 | $7.18M derived: sum of 3 quarters · filed 2026-05-15 | $11.01M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $2.31M 10-Q · filed 2026-02-13 | $5.13M derived: sum of 2 quarters · filed 2026-02-13 | $8.96M derived: sum of 3 quarters · filed 2026-02-13 | |
| 2024-09-30 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $6.65M derived: sum of 2 quarters · filed 2025-12-23 | $14.27M 10-K · filed 2025-12-23 | |
| 2024-06-30 | $3.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-12 | $11.45M 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $7.62M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |